Please use this identifier to cite or link to this item:
|Title:||Efficacy and Safety of Liraglutide versus Placebo as Add-on to Glucose Lowering Therapy in Patients with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial|
|Authors:||Davies, Melanie J.|
Bain, S. C.
Atkin, S. L.
Shamkhalova, M. S.
Umpierrez, G. E.
|Publisher:||American Diabetes Association|
|Citation:||Diabetes Care (In press, accepted manuscript)|
|Rights:||Copyright © American Diabetes Association, 2015. This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.|
|Description:||Deposited on acceptance in accordance with the Publisher's policy, available at http://diabetes.diabetesjournals.org/site/misc/ifora.xhtml#Section8|
|Appears in Collections:||Published Articles, Dept. of Cardiovascular Sciences|
Files in This Item:
|Full clean version Diabetes_Care_Davies_3916_maintext_refman_R2_20August2015.docx||Post-review (final submitted)||800.09 kB||Unknown||View/Open|
|Full clean version Diabetes_Care_Davies_3916_maintext_refman_R2_20August2015.pdf||Post-review (final submitted)||1.04 MB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.